FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2047813084> ?p ?o ?g. }

• W2047813084 endingPage "154" @default.
• W2047813084 startingPage "154" @default.
• W2047813084 abstract "Background: Irinotecan hydrochloride, a topoisomerase I inhibitor, is effective against small-cell lung cancer. Irinotecan also can act as a potential radiation sensitizer along with cisplatin. To evaluate efficacy and toxicity of irinotecan plus cisplatin (IP) with concurrent thoracic radiotherapy, we conducted a phase II study of IP followed by concurrent IP plus hyperfractionated thoracic radiotherapy in patients with previously untreated limited-stage small-cell lung cancer. Methods: Twenty-four patients with previously untreated small-cell lung cancer were enrolled onto the study since November 2004. Irinotecan was administered intravenously on days 1 and 8 in combination with cisplatin on day1 every 21 days. From the first day of third cycle, twice-daily thoracic irradiation (total 45 Gy) was given. Prophylactic cranial irradiation was given to the patients who showed complete remission after concurrent chemoradiotherapy. Restaging was done after second and sixth cycle with chest CT and/or bronchosocpy. Results: Up to November 2004, 19 patients were assessable. The median follow-up time was 12.5 months. A total of 99 cycles (median 5.2 cycles per patient) were administered. The actual dose intensity values were cisplatin /week and irinotecan /week. Among the 19 patients, the objective response rate was 95% (19 patients), with 9 patients (47%) having a complete response (CR). The major grade 3/4 hematological toxicities were neutropenia (35% of cycles), anemia (7% of cycles), thrombocytopenia (7% of cycles). Febrile neutropenia was 4% of cycles. The predominant grade 3/4 non-hematological toxicities was diarrhea (5% of cycles). Toxicities was not significantly different with concurrent administration of irinotecan and cisplatin with radiotherapy, except grade 3/4 radiation esophagitis (10% of patients). No treatment-related deaths were observed. The 1-year and 2-year survival rate of eligible patients was 89% (16/18) and 47% (9/18), respectively. Conclusion: Three-week schedule of irinotecan plus cisplatin followed by concurrent IP plus hyperfractionated thoracic radiotherapy is an effective treatment for limited disease small-cell lung cancer, with acceptable toxicity." @default.
• W2047813084 created "2016-06-24" @default.
• W2047813084 creator A5008393937 @default.
• W2047813084 creator A5012069848 @default.
• W2047813084 creator A5019819354 @default.
• W2047813084 creator A5021370060 @default.
• W2047813084 creator A5025033424 @default.
• W2047813084 creator A5056761846 @default.
• W2047813084 creator A5075086123 @default.
• W2047813084 creator A5090545099 @default.
• W2047813084 date "2007-01-01" @default.
• W2047813084 modified "2023-09-26" @default.
• W2047813084 title "Phase II Study of Induction Irinotecan + Cisplatin Chemotherapy Followed by Concurrent Irinotecan + Cisplatin Plus Twice-Daily Thoracic Radiotherapy" @default.
• W2047813084 cites W1586329649 @default.
• W2047813084 cites W1593461257 @default.
• W2047813084 cites W1839348318 @default.
• W2047813084 cites W1885320430 @default.
• W2047813084 cites W1892703858 @default.
• W2047813084 cites W1895855332 @default.
• W2047813084 cites W1905406155 @default.
• W2047813084 cites W1918962731 @default.
• W2047813084 cites W1961685780 @default.
• W2047813084 cites W1968626722 @default.
• W2047813084 cites W1971950362 @default.
• W2047813084 cites W1973510243 @default.
• W2047813084 cites W1997215830 @default.
• W2047813084 cites W2058680827 @default.
• W2047813084 cites W2068776651 @default.
• W2047813084 cites W2071351256 @default.
• W2047813084 cites W2073683299 @default.
• W2047813084 cites W2079713246 @default.
• W2047813084 cites W2113492722 @default.
• W2047813084 cites W2121464855 @default.
• W2047813084 cites W2124353451 @default.
• W2047813084 cites W2136570034 @default.
• W2047813084 cites W2150713507 @default.
• W2047813084 cites W2160012348 @default.
• W2047813084 cites W2166418266 @default.
• W2047813084 cites W2167050057 @default.
• W2047813084 cites W2323020638 @default.
• W2047813084 cites W2341745217 @default.
• W2047813084 cites W2407451361 @default.
• W2047813084 doi "https://doi.org/10.4046/trd.2007.63.2.154" @default.
• W2047813084 hasPublicationYear "2007" @default.
• W2047813084 type Work @default.
• W2047813084 sameAs 2047813084 @default.
• W2047813084 citedByCount "2" @default.
• W2047813084 countsByYear W20478130842012 @default.
• W2047813084 countsByYear W20478130842020 @default.
• W2047813084 crossrefType "journal-article" @default.
• W2047813084 hasAuthorship W2047813084A5008393937 @default.
• W2047813084 hasAuthorship W2047813084A5012069848 @default.
• W2047813084 hasAuthorship W2047813084A5019819354 @default.
• W2047813084 hasAuthorship W2047813084A5021370060 @default.
• W2047813084 hasAuthorship W2047813084A5025033424 @default.
• W2047813084 hasAuthorship W2047813084A5056761846 @default.
• W2047813084 hasAuthorship W2047813084A5075086123 @default.
• W2047813084 hasAuthorship W2047813084A5090545099 @default.
• W2047813084 hasConcept C121608353 @default.
• W2047813084 hasConcept C126322002 @default.
• W2047813084 hasConcept C143998085 @default.
• W2047813084 hasConcept C2776611710 @default.
• W2047813084 hasConcept C2776694085 @default.
• W2047813084 hasConcept C2778239845 @default.
• W2047813084 hasConcept C2780259306 @default.
• W2047813084 hasConcept C509974204 @default.
• W2047813084 hasConcept C526805850 @default.
• W2047813084 hasConcept C71924100 @default.
• W2047813084 hasConceptScore W2047813084C121608353 @default.
• W2047813084 hasConceptScore W2047813084C126322002 @default.
• W2047813084 hasConceptScore W2047813084C143998085 @default.
• W2047813084 hasConceptScore W2047813084C2776611710 @default.
• W2047813084 hasConceptScore W2047813084C2776694085 @default.
• W2047813084 hasConceptScore W2047813084C2778239845 @default.
• W2047813084 hasConceptScore W2047813084C2780259306 @default.
• W2047813084 hasConceptScore W2047813084C509974204 @default.
• W2047813084 hasConceptScore W2047813084C526805850 @default.
• W2047813084 hasConceptScore W2047813084C71924100 @default.
• W2047813084 hasIssue "2" @default.
• W2047813084 hasLocation W20478130841 @default.
• W2047813084 hasOpenAccess W2047813084 @default.
• W2047813084 hasPrimaryLocation W20478130841 @default.
• W2047813084 hasRelatedWork W2049010176 @default.
• W2047813084 hasRelatedWork W2138629171 @default.
• W2047813084 hasRelatedWork W2235203422 @default.
• W2047813084 hasRelatedWork W2353647715 @default.
• W2047813084 hasRelatedWork W2368228325 @default.
• W2047813084 hasRelatedWork W2408650435 @default.
• W2047813084 hasRelatedWork W2460868461 @default.
• W2047813084 hasRelatedWork W2471989939 @default.
• W2047813084 hasRelatedWork W2997709950 @default.
• W2047813084 hasRelatedWork W363598932 @default.
• W2047813084 hasVolume "63" @default.
• W2047813084 isParatext "false" @default.
• W2047813084 isRetracted "false" @default.
• W2047813084 magId "2047813084" @default.
• W2047813084 workType "article" @default.